ArticleTranscranial magnetic stimulation (2024)2025
Comparing synaptic mechanisms of iTBS and 10-Hz rTMS corticomotor plasticity.
Article in Transcranial magnetic stimulation (2024), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression
Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder
Who cites it
2 citing papers in PubMed.
- Effects of MRI-Navigated Intermittent Theta Burst Stimulation on Task Performance, Subjective Workload, and EEG Responses During Prolonged Simulated Flight: A Randomized Crossover Study.Bioengineering (Basel, Switzerland) · 2026Article
- Single-day accelerated TMS with D-cycloserine augmentation for depression: A placebo-controlled trial.Research square · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Introduction: Intermittent theta burst stimulation (iTBS) and 10-Hz repetitive transcranial magnetic stimulation (rTMS) appear clinically equivalent for the treatment of depression, but whether they share the same mechanism of action at the synaptic level is unknown. Methods: In this randomized, double-blind, placebo-controlled, eight-arm crossover study, we directly compared the influence of N-methyl-D-aspartate receptor (NMDAR) and gamma-aminobutyric acid receptor (GABAR) activity on iTBS and 10-Hz rTMS induced corticomotor plasticity in six healthy subjects using both permutation analysis and a linear mixed model with repeated measures of motor-evoked potentials (MEPs). Results: iTBS and 10-Hz produced nearly identical corticomotor plasticity in the placebo condition (p = 1.0), consistent with clinical equivalency. However, 10-Hz rTMS benefitted from NMDAR agonism with d-cycloserine (DCS) more than iTBS (β = 0.516, p < 0.001), which was partially attenuated by adding NMDAR antagonist dextromethorphan (DXM) to DCS. To test whether GABAR removal contributes to enhanced MEP excitability, as suggested by animal studies with 10-Hz, we reasoned that inhibition induced by GABAR agonism via lorazepam (LZP) would be less than at baseline, after GABAR removal by TMS. Instead, we found that neither protocol increased MEPs, but rather, MEPs were reduced in both protocols immediately (β = -0.172, p = 0.027) and 30 min after TMS (β = -0.183, p = 0.019). Discussion: Our exploratory pilot study is preliminary and requires replication to make any conclusions. Nevertheless, it is the first to compare the synaptic-level mechanisms of iTBS and 10-Hz rTMS, suggesting both iTBS and 10-Hz act predominantly through NMDAR-dependent LTP-like mechanisms rather than GABAergic mechanisms. The differential effects between protocols (i.e., 10-Hz produced more facilitation with DCS and more inhibition with LZP) could be accounted for by iTBS producing occlusion with DCS and compensatory facilitation with LZP, but this is speculative and requires preclinical work to confirm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.